EU reportedly in talks with J&J to secure doses of its COVID-19 vaccine

pharmafile | June 19, 2020 | News story | Medical Communications, Research and Development, Sales and Marketing COVID-19, EU, Europe, J&J, JJ, Vaccine 

It has been reported that the European Union is currently negotiating a deal with pharma giant Johnson & Johnson to reserve or buy upfront the COVID-19 vaccine the latter currently has in development.

The reports originated from the testimonies of two European Union health officials, Reuters reported. But due to the confidential nature of the discussions, forthcoming details on the potential deal were scarce.

The European Commission declined to comment on the story. Johnson & Johnson has been transparent about its efforts working with national governments and international organisation in its development of a vaccine candidate to combat COVID-19, but would not elaborate on speculation around a deal with the EU.

The pharma firm is set to push its candidate into human trials in July. It is anticipated that the deal between the company and the EU could be revealed as early as next week, but it is currently closely under wraps and there’s still a chance it could fall through.

If the story transpires to be true, the deal would mark the first partnership signed under the €2 billion emergency fund mandated by the EU across all 27 member states. The fund is designed to fund and secure the procurement of COVID-19 vaccine candidates from up to six different developers.

Matt Fellows

Related Content


GSK’s RSV vaccine approved in EU for older adults

GSK has announced that the European Commission (EC) has authorised Arexvy, the company’s respiratory syncytial …


European Parliament shares goal to tackle antimicrobial resistance

The European Parliament has shared its recommendations for a “coordinated EU response to health threats …

FDA approves Pfizer’s RSV vaccine for older adults

Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has …

Latest content